Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, non-randomized, phase II clinical trial conducted in
Canada. The purpose of the study is to determine the remission rate of acalabrutinib in
combination with R-CHOP in patients with previously untreated mantle cell lymphoma prior to
autologous stem cell transplantation. All patients will receive six cycles of R-CHOP
chemotherapy together with continuous acalabrutinib at the standard dose twice per day
orally. All patients will undergo response assessment at the end of six cycles of R-CHOP +
acalabrutinib with CT scan, PET/CT scan, and bone marrow biopsy. Responding patients will
proceed with stem cell mobilization, apheresis, and processing. Following ASCT, patients will
receive standard maintenance rituximab every 3 months for 2 years.